Real-Life Data of Osimertinib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation

被引：0
|
作者：
Alfaro Autor, C. [1 ]
Romero, A. [2 ]
Calvo De Juan, V. [1 ]
Franco, F. [1 ]
Sanchez Romero, E. [2 ]
Ortiz Cortes, N. [2 ]
Sanz Moreno, S. [1 ]
Rodriguez Festa, A. [1 ]
Serna Blasco, R. [1 ]
Barquin Del Romo, M. [1 ]
Provencio, M. [1 ]
机构：
[1] Hosp Puerta de Hierro Majadahonda, Oncol Med, Majadahonda, Madrid, Spain
[2] Hosp Puerta de Hierro Majadahonda, Liquid Biopsy Lab, Majadahonda, Madrid, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Osimertinib; Real-world data; EGFR mutant NSCLC;
D O I：
10.1016/j.jtho.2019.08.2296
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP1.14-11
引用
收藏
页码：S1036 / S1036
页数：1
相关论文
共 50 条
  • [1] Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
    Auliac, Jean Bernard
    Perol, Maurice
    Planchard, David
    Monnet, Isabelle
    Wislez, Marie
    Doubre, Helene
    Guisier, Florian
    Pichon, Eric
    Greillier, Laurent
    Mastroianni, Benedicte
    Decroisette, Chantal
    Schott, Roland
    Le Moulec, Sylvestre
    Arrondeau, Jennifer
    Cortot, Alexis B.
    Geriniere, Laurence
    Renault, Aldo
    Daniel, Catherine
    Falchero, Lionel
    Chouaid, Christos
    LUNG CANCER, 2019, 127 : 96 - 102
  • [2] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [3] The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
    Hizal, Mutlu
    Bilgin, Burak
    Paksoy, Nail
    Acikgoz, Ozgur
    Sezer, Ahmet
    Gurbuz, Mustafa
    Ak, Naziye
    Yucel, Sebnem
    Ayhan, Murat
    Erol, Cihan
    Demirkiran, Aykut
    Mandel, Nil Molinas
    Shbair, Abdallah
    Gokmen, Ivo
    Basoglu, Tugba
    Paydas, Semra
    Demiray, Atike Gokcen
    Iriagac, Yakup
    Sakalar, Teoman
    Zeynelgil, Esra
    Tatli, Ali Murat
    Bahceci, Aykut
    Guven, Deniz Can
    Caner, Burcu
    Can, Alper
    Gulmez, Ahmet
    Karakas, Yusuf
    Yalcin, Bulent
    Demirkazik, Ahmet
    Bilici, Ahmet
    Aydiner, Adnan
    Yumuk, Perran Fulden
    Sendur, Mehmet Ali Nahit
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (06) : 1501 - 1508
  • [4] The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
    Mutlu Hizal
    Burak Bilgin
    Nail Paksoy
    Özgür Açıkgöz
    Ahmet Sezer
    Mustafa Gürbüz
    Naziye Ak
    Şebnem Yücel
    Murat Ayhan
    Cihan Erol
    Aykut Demirkıran
    Nil Molinas Mandel
    Abdallah Shbair
    İvo Gökmen
    Tuğba Başoğlu
    Semra Paydaş
    Atike Gökçen Demiray
    Yakup İriağaç
    Teoman Şakalar
    Esra Zeynelgil
    Ali Murat Tatlı
    Aykut Bahçeci
    Deniz Can Güven
    Burcu Caner
    Alper Can
    Ahmet Gülmez
    Yusuf Karakaş
    Bülent Yalçın
    Ahmet Demirkazık
    Ahmet Bilici
    Adnan Aydıner
    Perran Fulden Yumuk
    Mehmet Ali Nahit Şendur
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1501 - 1508
  • [5] Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
    Peng, Da
    Shan, Dongfeng
    Dai, Chengcheng
    Li, Jie
    Wang, Zifan
    Huang, Ziyi
    Peng, Rui
    Zhao, Peng
    Ma, Xuezhen
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2033 - 2039
  • [6] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [7] Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer
    Jean-Bernard Auliac
    Karima Saboundji
    Michel Andre
    Jeannick Madelaine
    Gilles Quere
    Philippe Masson
    Alain Vergnenegre
    Régine Lamy
    Stéphane Raymond
    Anne-Marie Chiappa
    Pierre-Alexandre Hauss
    Pierre Fournel
    Romain Corre
    Christos Chouaid
    Targeted Oncology, 2019, 14 : 307 - 314
  • [8] Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer
    Auliac, Jean-Bernard
    Saboundji, Karima
    Andre, Michel
    Madelaine, Jeannick
    Quere, Gilles
    Masson, Philippe
    Vergnenegre, Alain
    Lamy, Regine
    Raymond, Stephane
    Chiappa, Anne-Marie
    Hauss, Pierre-Alexandre
    Fournel, Pierre
    Corre, Romain
    Chouaid, Christos
    TARGETED ONCOLOGY, 2019, 14 (03) : 307 - 314
  • [9] The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
    Pan, Guoqiang
    Chen, Kaiyan
    Yu, Xiaoqing
    Sheng, Jiamin
    Fan, Yun
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (06) : 2895 - 2905
  • [10] Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
    Lee, J. C.
    Yang, S.
    Oh, D. K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S806 - S807
12345